SQZ Biotechnologies Revenue 2020-2022 | SQZ

SQZ Biotechnologies revenue from 2020 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
SQZ Biotechnologies Annual Revenue
(Millions of US $)
2021 $27
2020 $21
2019 $20
SQZ Biotechnologies Quarterly Revenue
(Millions of US $)
2022-09-30 $3
2022-06-30 $3
2022-03-31 $3
2021-12-31 $12
2021-09-30 $5
2021-06-30 $5
2021-03-31 $5
2020-12-31 $2
2020-09-30 $6
2020-06-30 $6
2020-03-31 $6
2019-09-30 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.466B 9.42
GSK (GSK) United Kingdom $72.181B 8.99
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.127B 18.99
Ginkgo Bioworks Holdings (DNA) United States $3.783B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.566B 23.51
Biohaven (BHVN) United States $1.301B 0.00
Emergent Biosolutions (EBS) United States $0.658B 5.17
ADC Therapeutics SA (ADCT) Switzerland $0.393B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.065B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00